Johnson & Johnson
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer fourth quarter worldwide growth of 19% was "primarily the result" of the buyout of Merck's equity stake in the European nonprescription pharmaceutical business, J&J reports. Inspired by strong performance from Splenda, McNeil is "continuing to look at models and new opportunities to broaden that whole nutritional area, so we've got a whole organization looking at it" reports J&J CEO William Weldon. "We do feel there's a big opportunity, especially with the needs of childhood obesity and other things that are out there today." J&J global fourth quarter sales increased 13.3% to $12.8 bil...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: